Wegovy and Cannabis: What Women Need to Know About This Drug Interaction

The Short Answer on Whether Cannabis and Wegovy Interact

There is no published randomized controlled trial or pharmacokinetic study specifically examining cannabis alongside semaglutide 2.4 mg (Wegovy). That data gap is clinically significant. The absence of a study does not mean the combination is safe; it means clinicians are working from mechanism-based reasoning, case reports, and extrapolation from related research, rather than direct evidence.

What the existing science does show is that cannabis (particularly THC, the main psychoactive cannabinoid) and semaglutide act on overlapping physiological pathways: appetite regulation, gastric motility, nausea circuitry, and metabolic signaling. Those overlaps create at least three plausible pharmacodynamic interactions that women using Wegovy should understand before assuming the combination is harmless.

How Semaglutide Works in Your Body

Semaglutide 2.4 mg is a GLP-1 receptor agonist approved by the FDA for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. It works by mimicking glucagon-like peptide-1, a gut hormone that suppresses appetite via hypothalamic signaling, slows gastric emptying to extend satiety, and reduces food-reward signaling in the brain.

In the STEP 1 trial, participants using semaglutide 2.4 mg lost a mean of 14.9% of body weight over 68 weeks, compared with 2.4% in the placebo group. Women made up approximately 73% of the STEP 1 cohort, making this one of the more female-representative obesity-medicine trials published. Nausea was the most common adverse event, occurring in roughly 44% of participants on the active drug.

How Cannabis Acts on the Same Systems

THC binds to CB1 cannabinoid receptors, which are densely expressed in the hypothalamus, brainstem, and gut. Acutely, THC stimulates appetite (the "munchies" effect) by activating hypothalamic CB1 receptors and increasing ghrelin secretion. It also has antiemetic properties, which is why pharmaceutical cannabinoids like dronabinol are used for chemotherapy-induced nausea. CB1 receptors in the gastrointestinal tract regulate motility; THC activation typically slows gut transit, an effect that overlaps directly with semaglutide's gastric-emptying delay.

CBD (cannabidiol), the non-psychoactive cannabinoid in many products, has a different but related profile. CBD inhibits CYP3A4 and CYP2C9 enzymes at higher doses, which matters for any co-administered drug that uses those metabolic pathways. Semaglutide is not primarily metabolized by hepatic CYP enzymes; it is broken down by proteolytic cleavage. So a classical pharmacokinetic drug-drug interaction through CYP enzymes is unlikely with semaglutide specifically.

The Three Pharmacodynamic Concerns That Do Matter

Even without a CYP-mediated pharmacokinetic interaction, pharmacodynamic interactions can still change how you feel and how well Wegovy works. There are three main areas of concern.

1. Competing Effects on Appetite

Semaglutide suppresses appetite through GLP-1 receptor activation in the hypothalamus. THC stimulates appetite through CB1 receptor activation in overlapping hypothalamic nuclei. These are opposing signals acting on the same region of the brain.

In practice, this may mean cannabis blunts the appetite-suppressing effect you are supposed to feel from Wegovy, making it harder to stay in the caloric deficit that drives weight loss. No head-to-head study has quantified this blunting effect with semaglutide specifically, but preclinical models show clear cross-talk between GLP-1 and endocannabinoid signaling pathways in the hypothalamic arcuate nucleus. This is the most biologically plausible mechanism by which regular cannabis use could reduce your response to treatment.

2. Additive Slowing of Gastric Emptying

Semaglutide significantly delays gastric emptying, particularly during dose escalation. Cannabis (via CB1 receptors on enteric neurons) also slows gastric motility. Together, the additive delay may worsen nausea, vomiting, bloating, and early satiety beyond what either substance causes alone.

For women, this matters more than it might seem. Gastric emptying is already cycle-dependent: studies show that gastric emptying is measurably slower during the luteal phase of the menstrual cycle compared with the follicular phase, likely due to progesterone's inhibitory effect on gut motility. If you are adding semaglutide and cannabis on top of a high-progesterone luteal phase, you may be stacking three gastric-slowing forces simultaneously, which could make GI side effects significantly worse in the second half of your cycle.

3. Nausea and Vomiting: The Paradox

THC has antiemetic properties at typical recreational doses. You might expect this to help with Wegovy-induced nausea. The reality is more complicated.

Chronic or heavy cannabis use is associated with cannabinoid hyperemesis syndrome (CHS), a paradoxical condition characterized by cyclical severe vomiting that is only relieved by hot showers and cessation of cannabis. CHS is underdiagnosed and frequently mistaken for other GI conditions. If you develop new or worsening vomiting on Wegovy and you use cannabis regularly, CHS should be on your clinician's differential diagnosis list, not just a Wegovy side effect.

Occasional or low-dose cannabis use probably does not carry a meaningful CHS risk, but the threshold is not well-defined in the literature.

Women-Specific Physiology: How Your Hormones Change This Picture

The endocannabinoid system is not hormonally neutral. Estrogen and progesterone both modulate CB1 and CB2 receptor expression and endocannabinoid ligand levels across the menstrual cycle, pregnancy, and menopause. This makes the cannabis-semaglutide interaction a genuinely different question for women than for men, and yet almost no trial data addresses this directly.

Reproductive Years and the Menstrual Cycle

CB1 receptor sensitivity appears to fluctuate with estradiol levels. Animal studies demonstrate that estrogen upregulates CB1 receptor density in limbic regions, which may explain why women report stronger subjective effects from THC during the follicular phase (when estradiol is rising) compared with the luteal phase. If this translates to humans, the appetite-stimulating effect of cannabis may be stronger mid-cycle, precisely when many women using Wegovy are trying to maintain dietary adherence.

PCOS

If you have polycystic ovary syndrome, the cannabis interaction with Wegovy deserves extra attention. THC acutely elevates cortisol and can disrupt the pulsatile release of luteinizing hormone (LH) from the pituitary. Studies in women with PCOS show that LH pulsatility is already abnormal, and anything that further disrupts it may worsen the hormonal environment. Semaglutide has shown benefit for PCOS-related metabolic markers (insulin resistance, androgen levels) in small studies, but cannabis could theoretically work against those benefits by adding neuroendocrine disruption. No trial has addressed this combination directly in women with PCOS.

Perimenopause and Menopause

Women in perimenopause are increasingly using cannabis for sleep, anxiety, and vasomotor symptom management. CB1 receptors in the hypothalamus are involved in thermoregulation, and endocannabinoid tone changes substantially during the menopausal transition. This is biologically interesting, but not yet clinically well-characterized.

What is relevant for Wegovy users in perimenopause: the metabolic changes of the menopausal transition (visceral fat redistribution, insulin resistance, shifts in appetite-regulating hormones) are part of why GLP-1 therapy is increasingly considered for this population. Adding cannabis, which may blunt appetite suppression and add GI motility effects, may reduce your treatment response at a time when hormonal flux already makes weight management harder. The Menopause Society 2023 statement acknowledges the difficulty of weight management in the menopausal transition but does not address cannabis co-use specifically.

Trying to Conceive

Cannabis use is associated with reduced fertility in women, including longer time to conception and disrupted ovulation. Semaglutide is contraindicated during pregnancy (see the next section). If you are trying to conceive, you should stop Wegovy at least two months before attempting pregnancy, and you should also stop cannabis given its independent fertility effects.

Pregnancy, Lactation, and Contraception: Required Reading

Wegovy (semaglutide 2.4 mg) is contraindicated in pregnancy. This is not a relative contraindication. The FDA prescribing label states that semaglutide caused fetal harm in animal reproduction studies, and there are insufficient human data to establish safety. The label recommends discontinuing Wegovy at least two months before a planned pregnancy, because semaglutide has a long half-life of approximately one week and requires several weeks to clear fully.

Cannabis in Pregnancy

The CDC advises that no amount of cannabis use is known to be safe during pregnancy. THC crosses the placenta and accumulates in fetal tissue. Prenatal cannabis exposure is associated with low birth weight, preterm birth, and neurodevelopmental effects in offspring. The American College of Obstetricians and Gynecologists (ACOG Committee Opinion 722) recommends that women discontinue cannabis use before attempting pregnancy and throughout pregnancy and breastfeeding.

Contraception Requirement on Wegovy

Because Wegovy delays gastric emptying, it may reduce the absorption of oral contraceptive pills taken around the same time. The prescribing label specifically notes this potential interaction with oral contraceptives and recommends using a non-oral contraceptive method or a backup method during dose escalation, which lasts approximately 16 to 20 weeks. IUDs, implants, the patch, and the ring are all unaffected by gastric-emptying changes and are preferred options.

Lactation

Semaglutide is detectable in the milk of lactating rats; human lactation data are limited. The manufacturer recommends against use during breastfeeding. THC also transfers into breast milk, and ACOG and the AAP both advise against cannabis use while breastfeeding. Neither substance is appropriate during lactation.

Can You Drink Alcohol on Wegovy?

Since many women ask about alcohol alongside or instead of cannabis, a brief answer is warranted here. Alcohol and semaglutide interact in a clinically meaningful way. Semaglutide slows gastric emptying, which delays alcohol absorption and may change how quickly you feel its effects, potentially leading to miscalculation of intake. Many women on GLP-1 therapy report a reduced desire to drink; this is thought to involve GLP-1 receptors in the brain's reward circuitry. A small 2023 pilot study in alcohol use disorder found that semaglutide reduced alcohol craving scores, though this was in a specific clinical population and is not generalizable to all Wegovy users.

The more immediate risk with alcohol on Wegovy is hypoglycemia if you are also taking insulin or a sulfonylurea, and worsened nausea and vomiting from additive GI effects. Drinking on an empty stomach is riskier than usual because gastric emptying is already delayed.

Who This Is (and Is Not) Right For

Women for Whom Wegovy May Still Be Appropriate Despite Occasional Cannabis Use

If you use cannabis occasionally (a few times per month or less), use low-THC or CBD-dominant products, and do not have significant GI side effects from Wegovy, the theoretical interaction is less likely to cause clinically meaningful problems. You should still disclose cannabis use to your prescribing clinician, because it affects the differential diagnosis if nausea or vomiting worsens.

Women Who Should Think Carefully Before Combining These

• Women with PCOS relying on Wegovy to improve metabolic and hormonal markers
• Women in perimenopause using cannabis for symptom management who are starting Wegovy and need maximum weight-loss response
• Women with a history of CHS or unexplained cyclical vomiting
• Women actively trying to reduce HbA1c or manage prediabetes with Wegovy, where appetite blunting by cannabis could reduce treatment effect
• Women using oral contraceptive pills, where the combination of Wegovy's gastric-emptying delay plus cannabis may further complicate absorption timing

Women Who Should Not Use Either Substance

• Pregnant women or women trying to conceive
• Breastfeeding women
• Women with a history of cannabinoid hyperemesis syndrome
• Women with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (Wegovy carries a boxed warning for this risk regardless of cannabis co-use)

What the Evidence Gap Means for You

Women have historically been underrepresented in pharmacology and drug interaction studies. The STEP trials did enroll a majority of female participants, which is commendable, but no cannabis-interaction arm existed. Cannabis research more broadly has enrolled fewer women than men across most studies, and sex-stratified analyses of THC pharmacokinetics show that women tend to reach higher peak plasma THC concentrations than men at equivalent doses, likely due to differences in body fat distribution and CYP enzyme activity. Whether this translates to a stronger interaction with GLP-1 agents is genuinely unknown.

What is extrapolated: the appetite-opposing mechanism, the gastric-motility overlap, and the endocannabinoid-hormonal cross-talk. What is directly studied: essentially nothing specific to this combination in women.

That honesty matters. Your clinician cannot tell you "the research shows it is fine" because the research has not been done. The appropriate clinical position is one of caution and disclosure, not prohibition for every woman, and not reassurance that no interaction exists.

Practical Steps to Take Now

Disclose cannabis use to your Wegovy prescriber. Many women do not mention it, assuming it is irrelevant or that they will be judged. Your prescriber needs this information to interpret side effects accurately and to monitor your treatment response.

Track your GI symptoms by menstrual cycle phase. If nausea or vomiting is worse in your luteal phase (days 15 to 28 of a typical cycle), consider whether cannabis use on those days may be amplifying the progesterone-driven gastric-slowing that already occurs in the second half of your cycle.

If you are on an oral contraceptive pill and use cannabis edibles, be aware that both delayed gastric emptying (from Wegovy) and changes in gut motility (from cannabis) may affect when your pill is absorbed. Taking your pill at a consistent time, separate from both substances, reduces this risk. Talk to your prescriber about switching to a non-oral method during your first five months on Wegovy.

If you develop new or worsening cyclical vomiting and you use cannabis regularly, ask your clinician to consider CHS before attributing all symptoms to semaglutide. The distinction matters for management.

The next dose escalation step in Wegovy should be delayed, not accelerated, if you are having significant GI side effects. Adding cannabis that slows gastric motility while your body is still adjusting to a new dose is likely to make symptoms worse, not better.

For women in the trying-to-conceive stage: stop both Wegovy (two months before attempting conception) and cannabis (as soon as you begin trying, ideally before). Both carry meaningful reproductive risk and neither has an acceptable safety profile for pregnancy.